It may be because using EGFR-TKIs alone is able to make lung cancer with driver gene mutations get enough remission, and patients with EGFR, ALK, and RET mutations have a low response rate to ICIs because of the low PD-L1 expression [121,122,123]. The gene discussed is CD274; the disease is lung carcinoma.